Management of Cervical Cytology (Pap Smear) and HPV Test Co- This guideline serves as a guide to clinician and may not cover every clinical scenario
CERVICAL CANCER SCREENING Clinical Practice Guideline May 2016 These recommendations are systematically developed statements to assist practitioner and
Bethesda terminology for cervical cytology in clinical practice This includes addi- cussions of the current clinical management guidelines
European guidelines for quality assurance in cervical cancer screening – Second edition Laboratory Guidelines and Quality Assurance Practices for Cytology
2 women aged 21-29: cytology (Pap smear) alone every three years Updated Cervical Cancer Screening Guidelines Practice Advisory April 2021
cervical cancer control: a guide to essential practice (C4-GEP), precancerous lesions for cervical cancer prevention needed to be updated
It replaces the previous publication 'Guidance for Good Practice in Cervical Screening' 4th Edition Aims of Guidelines • To ensure that practice is in line
In November 2019 the National Cervical Screening Programme (NCSP) raised the recommended commencement age for screening to 25 years for any person with a cervix
Clinical Practice Guidelines Recommended Management Initiation of Screening Cervical cancer screening should begin at age 21 or three years after first
As per laboratory and colposcopy guidelines See table below Page 4 Cervical Cancer Screening May 2016 Clinical Practice Guideline
cervical cancer control: a guide to essential practice (C4-GEP), which was precancerous lesions for cervical cancer prevention needed to be updated
See the Clinical Considerations section {Reference #4) fu:r the relative detected by the Pap USPSTF guidelines for cervical cancer screening recommends: